mouse anti cd11b pe antibody  (Elabscience Biotechnology)

Journal: Cellular Oncology

Article Title: NR2F2/AGAP2 axis: regulating lipid synthesis to drive AML progression via AMPKα/ACC pathway

doi: 10.1007/s13402-026-01184-8

Figure Lengend Snippet: AGAP2 inhibited cell differentiation via targeting AMPK/ACC pathway. KG-1 and HL-60 cells were subjected to lentiviral transduction, and then were treated with 30 µM GSK621 for 48 h to activate AMPK. ( A ) Giemsa staining was used to assess cell morphology and differentiation, ×400 magnification. B , C . Analysis of differentiation marker CD11b expression by flow cytometry under AGAP2 overexpression. ( B ) Representative flow cytometry histograms; ( C ) Quantitative analysis of CD11b-positive cells. D , E . CD11b expression was analyzed by flow cytometry in cells co-transduced with a non-targeting control shRNA (NC), AGAP2-targeting shRNA (shAGAP2), or both AGAP2- and AMPKα1-targeting shRNAs (shAGAP2+ shAMPKα1). N = 3. The data were present as mean ± SD. N represents biological replicates. Error bars denote SD. * comparison of the EV group and AGAP2 group or comparison of the NC group and shAGAP2 group; * p < 0.05; ** p < 0.01; *** p < 0.005. # comparison of the AGAP2 group and AGAP2 + GSK621 group, or comparison of the shAGAP2 group and shAGAP2+shAMPKα1 group; # p < 0.05; ## p < 0.05; ### p < 0.005

Article Snippet: Subsequently, 100 μL of staining buffer was added and mixed thoroughly, followed by the addition of 5 μL of CD11b antibody (#E-AB-F1081D, Elabscience, China).

Techniques: Cell Differentiation, Transduction, Staining, Marker, Expressing, Flow Cytometry, Over Expression, Control, shRNA, Comparison

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: LILRB4 shapes an immunosuppressive microenvironment to drive cervical cancer progression through tumor-infiltrating myeloid cell expansion and CD8 + T-cell suppression

doi: 10.1007/s00018-026-06121-4

Figure Lengend Snippet: LILRB4 is highly expressed in human CC and correlates with tumor immunosuppression. ( A ) Volcano plots showing the differentially expressed genes (DEGs) in CC and non-cancer tissues. The cut-off was |Log2FC|≥1.5 and p value < 0.05. ( B ) Heatmap demonstrating the expression of DEGs enriched in 5 terms associated with T cells. The color scale represents scaled FPKM values. ( C ) Venn diagram showing the overlapping of the DEGs for the 5 terms in ( B ). ( D ) The mRNA levels of LILRB4, GZMB, PD-1, and CTLA-4 in CC and peritumorous tissues ( n = 29). ( E ) Correlation of the mRNA expression of LILRB4 with GZMB, PD-1, and CTLA-4 in CC. ( F ) Representative immunohistochemical staining images of CD8, CD4, and CD11b in LILRB4 high and low expression samples from CC tissues

Article Snippet: The antibodies used are listed below: PE CD85k (Gp49b) Monoclonal Antibody (Thermo Scientific, Pittsburgh, PA, USA, #12-5784-80), PerCP Anti-Mouse CD45 Antibody (Elabscience, Wuhan, China, #E-AB-F1136F), APC Anti-Mouse CD3 Antibody (Elabscience, Wuhan, China, #E-AB-F1013E), PE Anti-Mouse CD8a Antibody (Elabscience, Wuhan, China, #E-AB-F1104D), Alexa FluorTM 488 Ki-67 Monoclonal Antibody (Thermo Scientific, Pittsburgh, PA, USA, #53-5698-80), FITC Anti-Mouse IFN-γ Antibody (Elabscience, Wuhan, China, #E-AB-F1101UC), FITC TNF alpha Monoclonal Antibody (Thermo Scientific, Pittsburgh, PA, USA, #11-7321-41), PE Anti-Mouse/Human CD11b Antibody (Elabscience, Wuhan, China, #E-AB-F1081D), FITC Anti-Mouse F4/80 Antibody (Elabscience, Wuhan, China, #E-AB-F0995C), APC Anti-Mouse CD163 Antibody (Elabscience, Wuhan, China, #E-AB-F1295E), FITC Anti-Mouse Ly-6G/Ly-6 C (Gr-1) Antibody (Elabscience, Wuhan, China, #E-AB-F1120C), FITC granzyme B Monoclonal Antibody (Thermo Scientific, Pittsburgh, PA, USA, #11-8898-82), FITC Anti-Mouse CD279/PD-1 Antibody (Elabscience, Wuhan, China, #E-AB-F1131C), and CTLA-4 (BioLegend, San Diego, CA, USA, #106315).

Techniques: Expressing, Immunohistochemical staining, Staining